Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S is dated August 20, 2024. The document serves as a regulatory disclosure of share transactions conducted by the company's board members, executives, and associated persons in compliance with Article 19 of Regulation No. 596/2014 on market abuse. Novo Nordisk is a global healthcare company headquartered in Denmark, specializing in diabetes and other chronic diseases.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a specific insider trading transaction.
| Metric | Value |
|---|---|
| Transaction Type | Purchase of ADRs |
| Instrument | Novo Nordisk ADRs (NVO) |
| Total Volume | 1,500 ADRs |
| Total Value | DKK 1,368,944.39 |
| Transaction Date | August 19, 2024 |
| Exchange | New York Stock Exchange |
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It solely discloses a one-time purchase of securities by an insider.
Guidance, Outlook, and Risks
The document contains no management guidance, future outlook, risk factors, or discussion of contingencies. It is a mandatory compliance report regarding insider trading activity.
Key Facts for Investor Verification
- Insider Identity: The transaction was executed by Sylvie Louise Grégoire, a Member of the Board of Directors.
- Transaction Nature: The insider purchased 1,500 ADRs in a series of trades ranging from 1 to 431 shares at prices between DKK 912.34 and DKK 913.15.
- Regulatory Compliance: The disclosure was made pursuant to EU market abuse regulations and reported to the SEC as a foreign private issuer.
- Financial Scope: This filing provides no data on the company's overall financial health or quarterly performance.